Default

Oxford Expression Technologies Ltd.

No Reviews Yet
1 Order Completed
Oxford, GB

About Oxford Expression Technologies Ltd.

Founded: 2007 Type: Privately Held Size: 1-10 employees

Oxford Expression Technologies Ltd. (OET) has emerged from a collaboration between Oxford Brookes University and the Natural Environment Research Council. It provides products, services and consultancy to the global pharmaceutical and biotechnology industries from its base in Oxford, England, which has quickly become a world renowned centre of excellence for Baculovirus protein expression.

OET’s success has been built around our core technology, flashBACTM . flashBACTM is a one step high throughput Baculovirus based protein expression platform that enables fast and simultaneous production of multiple recombinant viruses suitable for small and large protein expression systems allowing scientists to produce proteins faster, more easily and cost-effectively.

OET will continue to branch out into other areas and applications of both insect and mammalian expression systems in order to broaden its portfolio. In particular OET has strong interests in novel applications such as Virus Like Particle production and the BacMam system, and is working in partnership with a number of other organisations.

In a short time its reputation has been forged as a world opinion leader and provider of products and services, contract consultancy and training for Baculovirus expression and is looking forward to even closer working relationships with the pharmaceutical and biotechnology industries to meet the needs of for high quality and cost-effective solutions for gene expression and protein production.

Our Services (9)


ic

Baculovirus Production

Price on request

Recombinant baculovirus is produced following co-transfection of insect cells with a transfer plasmid containing the gene of interest and flashBAC™ baculovirus DNA. The recombinant virus harvested from the co-transfection is then used to produce a high-titre amplified virus stock.


ic

Recombinant Protein Expression

Price on request

Oxford Expression Technologies is a name you can trust when it comes to baculovirus services and contract work. Our team of experts have over 25 years of experience with recombinant protein expression, having not only worked on it but helped to develop new and improved systems. During this time we have had the privilege of collaborating with major global clients including big pharma, governmental departments and academic research institutions.

We are able to provide a wide range of services which are available to view in more detail from the list on the right. From concept to completion, all projects are performed using the most up to date methods to ensure the highest quality throughout. OET also understands that every project is important which is why we offer assistance at every step of the way, with all our services tailored to individual needs and requirements. If you have a project or target in mind please contact us to see how we can help.


ic

Vaccine Production

Price on request

Oxford Expression Technologies (OET) is now able to apply its flashBAC baculovirus expression system to vaccine production, particularly in the exciting new field of virus like particle (VLP) vaccines. A virus like particle is an assembly of virus structural proteins that mimics the configuration of a real virus, except that it contains no genetic material. If a person is vaccinated with VLPs then an immune response is generated as if the immune system has been presented with a real virus. However as the VLPs do not contain any genetic material they are unable to replicate, and as such are harmless to the person who has been vaccinated. However, that person will now be protected against infection by the real (pathogenic) virus. These characteristics mean that the VLP platform has huge potential for use as an extremely effective anti viral vaccine.

However the production of VLPs is not without its problems. In order to produce a functional VLP that effectively mimics a real virus good yields of multiple virus structural proteins are needed. These must then be correctly assembled into a particle that reproduces the confirmation of the outer shell (capsid) of an infectious virus. The expression system used to produce the particles must be both safe and capable of producing multiple proteins both on a small scale (for testing) and on a larger scale (for vaccine manufacture).

The above requirements mean that VLP production can be a complex and difficult procedure. Unsurprisingly there has recently been considerable interest in the use of the baculovirus expression system for the production of VLP vaccines as it could overcome the above problems. As the FDA has recently licensed a baculovirus manufactured vaccine for use in humans (Cervarix® by GlaxoSmithKline) to protect against HPV this has now made it possible for the baculovirus system to be used more widely for VLP production. There is also significant interest in using the baculovirus system to produce VLPs that can be used to immunize against the influenza virus.

As the world opinion leaders in baculovirus expression technology, OET is very excited about the potential this field offers. The improvements in protein yield and quality offered by the flashBAC system, along with its capacity to produce multiple proteins means that it is ideally suited to VLP production. Moreover the scalability of the system and its high throughput compatibility makes VLP manufacture an economic proposition. OET also has expertise in performing the important quality control procedures involved in VLP purification to ensure that the final VLP preparation is pure and free of other unwanted components.

The field of VLP production is a very exciting area, and OET is ideally placed to maximise the potential of the baculovirus expression system for VLP production through our extensive expertise and our flashBAC technology. We have an active R&D effort in this field but we are also actively looking for partners with whom we could work. In this way we can develop, manufacture and commercialise a new generation of VLP vaccines, produced using the baculovirus expression system. If you are interested in partnering with OET to produce VLPs please contact us for a discussion of how we could work together.


ic

Protein Expression in Mammalian Cells

Mammalian cell based recombinant protein production
Price on request

Mammalian services including gene synthesis and cloning, transient expression, generation of stable cell lines, expression of recombinant protein, scale up, protein purification


ic

Gene Synthesis

Price on request

We can arrange the synthesis of any gene for you, and we’ll also work with any plasmid you supply as a starting point.


ic

Protein Expression Screening and Optimization

Price on request
Request a quote for more information about this service.

ic

Bacterial Protein Expression

Price on request
Request a quote for more information about this service.

ic

Protein Purification

Price on request
Request a quote for more information about this service.

ic

Baculovirus/Insect Cell Protein Expression

Price on request
Request a quote for more information about this service.

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.

Oxford Expression Technologies Ltd. has not received any reviews.

Oxford Expression Technologies Ltd. has not received any endorsements.